Skip to content Skip to footer
Subscribe Now
Alvotech & Advanz Pharma
NEWS

Alvotech and Advanz Pharma Reports the EMA’s MAA Acceptance of AVT05 (Biosimilar, Simponi) 

Shots:  The EMA has accepted the MAA of AVT05, biosimilar version of J&J's Simponi & Simponi Aria (golimumab), for the treatment of several chronic inflammatory diseases, with the decision expected in Q4’25  Alvotech, in Apr 2024, reported top-line data from a confirmatory trial of AVT05 vs Simponi in patients with moderate to severe rheumatoid arthritis,…
November 4, 2024

Read more

NEWS

Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi) 

Shots:  Bio-Thera and STADA have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab)  Under the collaboration, Bio-Thera is entitled to receive a $10M upfront and an additional $147.5M development and commercial milestones upon certain conditions fulfilment  Furthermore, Bio-Thera will handle the development, manufacturing and supply activities of…
May 28, 2024

Read more

Disease of the Month- Juvenile Arthritis
INSIGHTS+

Disease of the Month- Juvenile Arthritis

Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots brings this month a summary of Juvenile arthritis, an autoimmune inflammatory disease   July is observed…
July 13, 2023

Read more